FY2026 EPS Estimate for Globus Medical Increased by Analyst

Globus Medical, Inc. (NYSE:GMED) – Investment analysts at Zacks Research raised their FY2026 earnings estimates for Globus Medical in a research note issued on Tuesday, March 10th. Zacks Research analyst Team now anticipates that the medical device company will post earnings of $4.40 per share for the year, up from their previous estimate of $3.85. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Zacks Research also issued estimates for Globus Medical’s Q4 2026 earnings at $1.37 EPS, Q1 2027 earnings at $1.07 EPS, Q2 2027 earnings at $1.14 EPS, Q3 2027 earnings at $1.21 EPS and FY2027 earnings at $4.66 EPS.

Globus Medical (NYSE:GMED) last posted its earnings results on Tuesday, February 24th. The medical device company reported $1.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.22. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. The business had revenue of $826.42 million for the quarter, compared to analysts’ expectations of $803.29 million. During the same period in the prior year, the company posted $0.84 EPS. The business’s revenue for the quarter was up 25.7% compared to the same quarter last year.

Several other equities analysts have also recently commented on the company. Barclays boosted their target price on Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Wall Street Zen upgraded shares of Globus Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 3rd. Wells Fargo & Company increased their target price on Globus Medical from $98.00 to $104.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. Royal Bank Of Canada raised their price target on Globus Medical from $92.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Finally, Needham & Company LLC upped their price objective on Globus Medical from $112.00 to $114.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $104.36.

Globus Medical Stock Performance

Globus Medical stock opened at $87.22 on Thursday. Globus Medical has a fifty-two week low of $51.79 and a fifty-two week high of $101.40. The stock has a market cap of $11.80 billion, a P/E ratio of 22.14, a PEG ratio of 2.02 and a beta of 1.05. The firm’s fifty day moving average price is $90.82 and its 200-day moving average price is $78.05.

Hedge Funds Weigh In On Globus Medical

Several hedge funds have recently made changes to their positions in the business. SBI Securities Co. Ltd. raised its stake in Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after buying an additional 167 shares in the last quarter. Advisory Services Network LLC purchased a new position in shares of Globus Medical in the 3rd quarter valued at approximately $26,000. EverSource Wealth Advisors LLC lifted its stake in shares of Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares during the period. Advisors Asset Management Inc. bought a new stake in shares of Globus Medical during the second quarter valued at approximately $28,000. Finally, Larson Financial Group LLC boosted its position in shares of Globus Medical by 83.4% during the fourth quarter. Larson Financial Group LLC now owns 532 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 242 shares in the last quarter. 95.16% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Globus Medical news, EVP Kelly Huller sold 20,000 shares of the firm’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total value of $1,890,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Leslie V. Norwalk sold 2,000 shares of the stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $101.10, for a total transaction of $202,200.00. Following the sale, the director owned 10,419 shares of the company’s stock, valued at approximately $1,053,360.90. This represents a 16.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 35,594 shares of company stock valued at $3,332,253. 18.51% of the stock is currently owned by insiders.

Key Headlines Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research raised EPS estimates across Q1–Q4 (2026–2027) and issued an FY2028 projection of $5.18, maintaining a “Strong‑Buy” rating — this boosts earnings credibility and upside expectations.
• Positive Sentiment: Short interest dropped ~30% in February to ~3.27M shares (≈3.0% of float), lowering potential selling pressure and shortening the days‑to‑cover to about 2.3 days — a constructive technical development.
• Positive Sentiment: Q4 results and Nevro update refreshed the investment story: Q4 revenue and EPS beats support the raised estimates and near‑term momentum. How The Globus Medical (GMED) Investment Story Is Evolving After Q4 Results And Nevro Update
• Positive Sentiment: GMED was included in a Zacks list of 5 medical instruments stocks with short‑term upside, highlighting favorable analyst attention and thematic tailwinds (AI, M&A, product pipeline). 5 Medical Instruments Stocks to Buy Amid Huge Short-Term Price Upside
• Neutral Sentiment: The company reaffirmed its 2026 outlook, prompting discussion about capital allocation priorities (share repurchases vs. M&A/investment) — signals stability but decisions will drive long‑term allocation impact. Does Globus Medical’s (GMED) Reaffirmed 2026 Outlook Reveal Its Next Capital Allocation Priorities?
• Neutral Sentiment: Analysts and value models are reassessing fair value after recent share weakness—this has generated more coverage and volatility but not new negative company fundamentals. Assessing Globus Medical (GMED) After Recent Share Price Weakness And Fair Value Signals

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.